{"text": "The median proportion of utterances with echolalia was 0.16.", "user_data": {"pmid": "10230191"}}
{"text": "No differences were found between the naltrexone and placebo conditions in any of the measures of children or parents' communication.", "user_data": {"pmid": "10230191"}}
{"text": "Significant correlations were found between the child's number of words and developmental quotient (Spearman rho = 0.58, p = .003) and between the child's and parent's number of words (rho = 0.55, p = .005).", "user_data": {"pmid": "10230191"}}
{"text": "Of the 60 children, 4 could not be evaluated - 2 received secretin outside the study, and 2 did not return for follow-up.", "user_data": {"pmid": "10588965"}}
{"text": "Thus, 56 children (28 in each group) completed the study.", "user_data": {"pmid": "10588965"}}
{"text": "As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures.", "user_data": {"pmid": "10588965"}}
{"text": "None of the children had treatment-limiting adverse effects.", "user_data": {"pmid": "10588965"}}
{"text": "Amantadine was well tolerated.", "user_data": {"pmid": "11392343"}}
{"text": "Both groups had symptom reduction.", "user_data": {"pmid": "11501687"}}
{"text": "Subjects showed improvement on the CPRS Autism Factor (F1,9 = 24.4, p = .0008).", "user_data": {"pmid": "11501687"}}
{"text": "Side effects included drowsiness and weight gain.", "user_data": {"pmid": "11501687"}}
{"text": "The other measures showed no treatment effect for secretin compared with placebo.", "user_data": {"pmid": "11699803"}}
{"text": "Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).", "user_data": {"pmid": "12151468"}}
{"text": "In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months.", "user_data": {"pmid": "12151468"}}
{"text": "Sixty one children completed the study.", "user_data": {"pmid": "12876177"}}
{"text": "After randomisation, there were no significant differences in gender, race, age, and parent and teacher GBRS and Ritvo Scale between the two groups.", "user_data": {"pmid": "12876177"}}
{"text": "Compared with placebo, secretin treatment was not associated with significant improvement of CSBS standard scores from baseline to 2 or 4 weeks post-infusion.", "user_data": {"pmid": "12876177"}}
{"text": "There were no significant changes in gastrointestinal symptoms after HSS or saline placebo.", "user_data": {"pmid": "12876177"}}
{"text": "The most common symptoms identified by parents were tantrums, aggression, and hyperactivity.", "user_data": {"pmid": "14627879"}}
{"text": "Interrater reliability was excellent.", "user_data": {"pmid": "14627879"}}
{"text": "Ratings were collinear with Clinical Global Impression-Improvement and Aberrant Behavior Checklist Irritability subscale (primary dimensional measure).", "user_data": {"pmid": "14627879"}}
{"text": "Effect size d was 1.4, compared to 1.2 on the Aberrant Behavior Checklist Irritability subscale.", "user_data": {"pmid": "14627879"}}
{"text": "Effect sizes varied twofold by symptom category, largest for self-injury (2.11) and tantrums (1.95).", "user_data": {"pmid": "14627879"}}
{"text": "Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo.", "user_data": {"pmid": "15492353"}}
{"text": "Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the ABC; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.", "user_data": {"pmid": "15492353"}}
{"text": "Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure.", "user_data": {"pmid": "15492353"}}
{"text": "Extrapyramidal symptoms scores were comparable between groups.", "user_data": {"pmid": "15492353"}}
{"text": "Part I included 63 children.", "user_data": {"pmid": "15994720"}}
{"text": "The change on the Aberrant Behavior Checklist irritability subscale was small and clinically insignificant.", "user_data": {"pmid": "15994720"}}
{"text": "Reasons for discontinuation of part I included loss of efficacy (N=5) and adverse effects (N=1).", "user_data": {"pmid": "15994720"}}
{"text": "The subjects gained an average of 5.1 kg.", "user_data": {"pmid": "15994720"}}
{"text": "Part II included 32 patients.", "user_data": {"pmid": "15994720"}}
{"text": "For sleeping behavior, midazolam was found to be significantly more effective than diazepam as the duration of stimulation increased (P<.05).", "user_data": {"pmid": "16173223"}}
{"text": "For the movement and crying behaviors, midazolam also proved to be significantly more effective from the start of treatment through the 35- and 40-min markers, respectively (P<.05).", "user_data": {"pmid": "16173223"}}
{"text": "For the remainder of treatment, however, there was no statistically significant difference in these behaviors between the trials (P>.05).", "user_data": {"pmid": "16173223"}}
{"text": "Weight gain, increased appetite, anxiety, and fatigue were the most frequently reported side effects.", "user_data": {"pmid": "16239862"}}
{"text": "Methylphenidate was superior to placebo on the primary outcome measure, with effect sizes ranging from 0.20 to 0.54 depending on dose and rater.", "user_data": {"pmid": "16275814"}}
{"text": "Seven children completed the trial.", "user_data": {"pmid": "16919138"}}
{"text": "In 2004-2005, 12 boys and 4 girls (7 with autistic disorder, 1 Asperger's, 8 pervasive developmental disorder not otherwise specified) all completed at least 3 weeks of each condition.", "user_data": {"pmid": "17003665"}}
{"text": "On the primary outcome, the Hyperactivity subscale of the Aberrant Behavior Checklist, ATX was superior to placebo (p =.043, effect size d = 0.90).", "user_data": {"pmid": "17003665"}}
{"text": "It was also superior on a 0 to 3 rating of nine DSM-IV ADHD hyperactive/impulsive symptoms (p =.005, d = 1.27), but missed significance on nine inattentive symptoms (p =.053, d= 0.89).", "user_data": {"pmid": "17003665"}}
{"text": "Adverse events were otherwise tolerable, with no tendency to stereotypy.", "user_data": {"pmid": "17003665"}}
{"text": "The scores of IQ or DQ had increased and scores of ABC had dropped.", "user_data": {"pmid": "19727232"}}
{"text": "The differences between the two groups were greatly significant in statistics (P < 0.01).", "user_data": {"pmid": "19727232"}}
{"text": "The decreasing level of both ABC scores and the increasing level of the IQ scores were negatively correlated with age, and the decreasing level of ABC scores was in line regression(positive correlation) with base IQ.", "user_data": {"pmid": "19727232"}}
{"text": "Primary: intent-to-treat random effects regression showed that COMB was superior to MED on HSQ (p = .006) [effect size at week 24 (d) = 0.34].", "user_data": {"pmid": "19858761"}}
{"text": "Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, COMB showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04).", "user_data": {"pmid": "19858761"}}
{"text": "Final risperidone mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg) (p = .04).", "user_data": {"pmid": "19858761"}}
{"text": "Compared with children who received community-intervention, children who received ESDM showed significant improvements in IQ, adaptive behavior, and autism diagnosis.", "user_data": {"pmid": "19948568"}}
{"text": "The ESDM group maintained its rate of growth in adaptive behavior compared with a normative sample of typically developing children.", "user_data": {"pmid": "19948568"}}
{"text": "In contrast, over the 2-year span, the comparison group showed greater delays in adaptive behavior.", "user_data": {"pmid": "19948568"}}
{"text": "Children who received ESDM also were more likely to experience a change in diagnosis from autism to pervasive developmental disorder, not otherwise specified, than the comparison group.", "user_data": {"pmid": "19948568"}}
{"text": "Mean improvement in Aberrant Behavior Checklist irritability subscale score was significantly greater with aripiprazole than with placebo from week 1 through week 8.", "user_data": {"pmid": "19948625"}}
{"text": "Aripiprazole demonstrated significantly greater global improvements than placebo, as assessed by the mean CGI-I score from week 1 through week 8; however, clinically significant residual symptoms may still persist for some patients.", "user_data": {"pmid": "19948625"}}
{"text": "No serious AEs were reported.", "user_data": {"pmid": "19948625"}}
{"text": "152 children were recruited.", "user_data": {"pmid": "20494434"}}
{"text": "77 were assigned to PACT (London [n=26], Manchester [n=26], and Newcastle [n=25]); and 75 to treatment as usual (London [n=26], Manchester [n=26], and Newcastle [n=23]).", "user_data": {"pmid": "20494434"}}
{"text": "Treatment effect was positive for parental synchronous response to child (1.22, 0.85 to 1.59), child initiations with parent (0.41, 0.08 to 0.74), and for parent-child shared attention (0.33, -0.02 to 0.68).", "user_data": {"pmid": "20494434"}}
{"text": "Effects on directly assessed language and adaptive functioning in school were small.", "user_data": {"pmid": "20494434"}}
{"text": "Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from baseline after sham depletion (P = .001).", "user_data": {"pmid": "8911222"}}
{"text": "Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).", "user_data": {"pmid": "8911222"}}
{"text": "In addition, patients were significantly less calm and happy and more anxious.", "user_data": {"pmid": "8911222"}}
{"text": "No significant change was observed in social relatedness or repetitive thoughts and behavior.", "user_data": {"pmid": "8911222"}}
{"text": "Patients who had a significant global exacerbation of symptoms had significantly higher baseline plasma total tryptophan levels (P < .001) and Autism Behavior Checklist scores (P = .005) than did patients who showed no significant change in symptoms after tryptophan depletion.", "user_data": {"pmid": "8911222"}}
{"text": "Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).", "user_data": {"pmid": "8911223"}}
{"text": "Treatment response was not correlated with age level of autistic behavior, or full-scale IQ.", "user_data": {"pmid": "8911223"}}
{"text": "Other than mild sedation and nausea in a few patients, fluvoxamine was well tolerated.", "user_data": {"pmid": "8911223"}}
{"text": "No dyskinesias, adverse cardiovascular events, or seizures occurred.", "user_data": {"pmid": "8911223"}}
{"text": "Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).", "user_data": {"pmid": "9672054"}}
{"text": "Objective, measurable change in social behavior and language did not occur.", "user_data": {"pmid": "9672054"}}
{"text": "Other than mild, transient sedation, risperidone was well tolerated, with no evidence of extrapyramidal effects, cardiac events, or seizures.", "user_data": {"pmid": "9672054"}}
